Acute thrombosis occurs during or early after intervention, and subacute thrombosis occurs within the subsequent 30 days. Both usually present with unstable symptoms and angiographic evidence of thrombus. However, the definition of late thrombosis may be problematic. It may not present with symptoms. It may be detected only when follow-up angiography shows a late total occlusion, which could also be the result of progressive intimal hyperplasia. Late total occlusion/thrombosis should be defined as any angiographically documented total occlusion Ͼ30 days after the procedure. For patients who have a patent treatment site at 6 months and subsequently develop a total occlusion, we propose the term "late late thrombosis." Based on these new definitions, the investigators presented 4 patients with late thrombosis and 2 with late late thrombosis.
Is Late Thrombosis a Known Phenomenon
After Conventional PTCA or Stenting?
The literature identifies patients at risk for late reocclusion after conventional PTCA. Total occlusions treated with stenting are reported to have a 7% rate of recurrence of late total occlusion at 6 months. 3 Treatment of an infarct-related vessel is associated with a 30% reocclusion rate after thrombolytic therapy at 3 months 4 and up to a 17% rate of reocclusion after PTCA at 6 months. 5 The majority of these events were clinically silent, and the proposed causes were rethrombosis or progressive renarrowing. Patients treated with stents and ticlopidine rarely present with late thrombosis. 6
Late Thrombosis in Clinical Radiation Trials
The patients in the current series were not considered highrisk patients when they were enrolled in the radiation protocol, although 4 of 6 had contributing factors. The first question is whether late thrombosis occurs in other radiation clinical trials." Feasibility trials typically include highly selective small cohorts of patients, usually lack control groups, and have nonuniform anticoagulation/antithrombotic drug regimens; thus, complications that occur in Ͻ10% of patients can be easily missed. We reviewed the reported cases of late thrombosis/occlusion for each of the completed and published feasibility radiation studies. Condado et al 1 treated 21 patients with ␥-radiation ( 192 Ir after balloon angioplasty, with doses that exceeded 55 Gy to the near wall) and discharged all patients with aspirin and coumadin for a period of 3 months. Two patients developed silent thrombosis (at 30 and 38 days after treatment) without ECG evidence of MI. One of these patients had primary total occlusion and the other had a severe post-PTCA dissection before radiation. 1 None of the other 19 patients had late total occlusion at 2-year angiographic follow-up. 7 Verin and coworkers 8 treated 15 patients by application of ␤-radiation ( 90 Y) after balloon angioplasty of de novo lesions. Patients were discharged with aspirin as sole antiplatelet therapy. At 6 months, none of the patients had clinical or angiographic evidence of thrombosis, but 1 asymptomatic patient had total occlusion.
In the Beta Energy Restenosis Trial (BERT), 9 23 patients with de novo lesions were treated with balloon angioplasty plus intracoronary radiation with 90 Sr/Y (a pure ␤-emitter). Patients were discharged with no antiplatelet agent other than
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aspirin. At 6 months, only 1 patient presented with a late total occlusion. Conversely, in the middle of the Beta Cath study, a randomized study that used the same radiation system, prescription dose, and antiplatelet regimen as in BERT, the data safety monitoring committee advised a change in the antithrombotic regimen of the provisional stent arm to 3 months of ticlopidine due to an excess of late thrombosis.
In the SCRIPPS trial (Scripps Coronary Radiation to Inhibit Proliferation Post Stenting), 10 55 patients with restenosis were randomized to either placebo (29 patients) or 192 Ir (26 patients) and were discharged with ticlopidine and aspirin for 3 months only if new stents were implanted. At 2 years, there were 2 MIs associated with deaths in the placebo group, whereas only 1 patient from the irradiated group developed stent thrombosis and MI at day 18 due to early cessation of ticlopidine. 11 In the WRIST study (Washington Radiation for In-Stent Restenosis Trial), patients with in-stent restenosis were randomized to either placebo or radioactive 192 Ir seeds after conventional treatment of in-stent restenosis. The anticoagulation protocol for all patients was aspirin and ticlopidine for 1 month. Late total occlusion (at 6 months) was documented in 5 (7.7%) of 65 patients in the irradiated group (2 were asymptomatic) versus 3 (4.6%) of 65 in the control group (all symptomatic) (Waksman et al, unpublished data, 1999) .
In BETA WRIST (Beta Radiation for WRIST), 12 In the study by Costa et al, 2 the late thrombosis rate reported was 6.6%. However, a substantial number of patients did not complete the 6-month angiographic follow-up. Thus, an additional number of patients may develop symptomatic or silent late thrombosis that will be detected by angiography, and it is likely that by the time this report reaches the readers, the actual late thrombosis rate will be higher. In addition, late thrombosis rates appear to be higher in patients treated with stents plus radiation (4/45 or 8.8%) versus patients treated with balloons plus radiation (2/63 or 3.2%)
Delayed Healing and/or Platelet Recruitment
The second question is, why late thrombosis? Is it the patient, the stent, the operator, or the radiation? Potential causes for late thrombosis are listed in the Table. Late thrombosis, not neointimal hyperplasia, is probably the major cause of late total occlusion after intracoronary radiation therapy. Although not absolutely conclusive, the evidence is as follows.
Ionizing radiation inhibits neointima formation after vascular injury, as shown in numerous studies in the porcine model of restenosis. 13, 14 Most cases of radiation treatment failure are focal (ie, edge stenosis), not diffuse progressive occlusive disease. The majority of patients with late total occlusion after radiation therapy presented with acute events similar to subacute thrombosis.
There is increased evidence from animal studies that radiation induces thrombosis and that the thrombosis rate is related to the dose. Our studies 15 showed luminal thrombi after radiation consisting mostly of fibrin, less organized than thrombus found in nonirradiated arteries after vascular injury. Furthermore, thrombi present in irradiated arteries lacked cells thought to be involved in the healing response to arterial injury (monocytes, lymphocytes, and macrophages); this may prolong the platelet residence and delay thrombus organization. 15 Others 16 demonstrated a dose-dependent recruitment of platelets at the site of injury and irradiation.
Stents may increase the risk of late thrombosis by being more thrombogenic, and radiation may further delay complete reendothelialization. Delayed healing was seen at 12 weeks with the radioactive stent. 17 It is possible that the new endothelium may be dysfunctional, causing arterial spasm and flow impairment.
Unhealed dissections were also seen (both angiographically and by intravascular ultrasound at 6-month follow-up) in some patients who were treated with balloon angioplasty and intracoronary radiation. 18 A different explanation is required for the striking phenomenon of late late thrombosis seen many months after a patent artery was documented at 6-month angiographic follow-up. At this time, we don't know what the incidence, timing, and mechanism of this new phenomenon are or how to prevent it.
Is it possible that a gradual erosion of tissue surrounding the stent, leaving the stent unopposed to the vessel wall, will serve as a nidus for thrombosis? The intravascular ultrasound studies of patients who underwent radiation in the WRIST studies demonstrated reduction of in-stent neointimal tissue at follow-up in Ͼ50% of patients. This could be paralleled by a reduction in the peri-stent tissue, causing the stents to become unopposed to the vessel wall.
Clinical Implications and Therapeutic Strategy
There are advantages to the rapid identification of complications of a new technique, because therapeutic strategies to prevent these complications may be included in the early pivotal trials. In the past, adjunct antiplatelet therapy with ticlopidine proved to be effective in reducing acute and subacute thrombosis in the STent arterial Anticoagulation Regimen Study (STARS). 19 Now, the important questions are (1) whether prolonged antiplatelet therapy for patients treated with intracoronary radiation will be effective, and (2) what should be the duration of prolonged antiplatelet therapy? 
Final Comments and Conclusions
New technologies continue to surprise us with unexpected events that need to be disclosed fully and evaluated carefully. Describing a true new phenomenon from only 6 cases is like shooting in the air and hitting the right bird with the first bullet. Costa and his coworkers should be congratulated. However, we still don't know why the bird was there, where it came from, and what its final destination was. It therefore becomes essential to define the true incidence and origin of late thrombosis, as well as the factors that contribute to it. Multivariate analysis of larger patient cohorts will be required to determine clinical and angiographic predictors of late thrombosis, and clinical therapeutic strategies will be found to prevent it. The control of late thrombosis will strengthen vascular brachytherapy, and the winner will be the patient, who will be able to enjoy the honey without feeling the sting.
